Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.

Mirxes said in a statement this Series D funding is anchored by existing and new investors, including Beijing Fupu which the Management Committee of Zhejiang Anji Economic Development Zone indirectly owned a majority stake.

EDB Investments Pte Ltd, wholly owned by the Singapore Economic Development Board, Agency for Science, Technology and Research, Singapore’s lead public sector research and development (R&D) agency for scientific discovery and technological innovation, Mitsui & Co., Ltd., a company which is listed in various stock exchanges in Japan, and NHH Venture Fund, also participated in the round.

According to the statement, the funding will play a pivotal role in accelerating Mirxes’s delivery of cutting-edge cancer early detection blood tests and preventive healthcare solutions in major markets.

The fresh investment will be used primarily to scale adoption and penetration of Mirxes’s flagship stomach cancer blood test, GASTROClearTM in major Asia-Pacific markets including Southeast Asia, China and Japan.

It will also be used to accelerate the development and commercialization of Mirxes’s maturing clinical pipeline, including a blood-based colorectal cancer screening test and the multi-cancer early detection test under Project CADENCE, an ambitious project to develop a single blood test for early detection of nine high mortality cancers, powered by the company’s first-in-class RNA technology and other complementary biomarker technologies.

“Amid challenging macro-environment, this new investment further validates the clinical and socio-economic impact of our proprietary miRNA technology platform, and continues to position Mirxes as a frontrunner in the global fight against cancer through early detection,” said Dr. Zhou Lihan, Co-Founder and Chief Executive Officer of Mirxes.

According to him, this fresh funding will fuel the firm’s ambitious growth plans and enable it to continue making a significant impact in the field of multi-cancer early detection.

Mirxes is a RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale.

The company’s commitment to be a leading RNA centric multi-omics technology company that provides accurate, accessible, and actionable diagnostic solutions to address critical unmet clinical needs across the care continuum, has propelled it towards the listing, which will provide enhanced opportunities for investors and further bolster Mirxes’s global position.

With a strengthened financial position, expanded market presence, and a strategic partnership, Mirxes said it is well-equipped to drive forward its mission of making early disease detection accessible on a global scale.

It said that these developments demonstrate its unwavering commitment to alleviate cancer burden and reduce healthcare costs by leveraging innovative RNA tests that detect diseases earlier, improving health economics and outcomes to foster a healthier future for communities worldwide.

MiRXES secures $77M Series C funding to accelerate multi-cancer early detection pipeline